5 Key Takeaways

• 1

  Lebrikizumab met co-primary and key secondary end points in pediatric patients with moderate-to-severe atopic dermatitis in the Phase 3 ADorable-1 trial.

• 2

  In the trial, 63% of patients on lebrikizumab achieved a 75% reduction in EASI score, compared to 22% in the placebo group.

• 3

  The trial showed that 44% of lebrikizumab patients had an IGA score of 0 or 1, indicating clear skin, versus 15% with placebo.

• 4

  Lebrikizumab's safety profile was consistent with previous studies, with common adverse events being upper respiratory infections and nasopharyngitis.

• 5

  The ongoing ADorable-2 study will follow patients for up to 52 weeks, as lebrikizumab aims for potential label expansion for younger patients.